Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Check this out....http://seekingalpha.com/article/45704-optimer-pharma-to-talk-collaboration-with-c-o-on-cross-licensing-products
C & o website..
Its in chinese...http://www.changao.com/
Who in their right mind would short this stock!!! lol
Looks like volume is picking up.
Low 20's on approval along with the short covering...
Based on IHUB this stock is almost 10% shorted!!!
That's what I have pounding on the table. Low 20's is my target.
"Dificid may generate $500 million a year in sales, Carr said in a telephone interview"
There is our $24 pps if true !!!
Don't forget the HUGE short interest , low float....
This has the makings of a BIG run on approval, imo
Almost 64% of this stock is owned....It wont take much for this pps to run up BIG..
Holdings
Total Number of Shares Held 29,718,625
Large Block Owners 85
Percent Shares Owned 63.70%
Percent Change in Ownership 0.34%
0.30% Brokerage Firms
61.00% Investment Managers
2.40% Strategic Entities
36.30% Non-Institutional
Regional Holdings
North America 55.40%
Europe 8.30%
Unknown 0.00%
Monthly Share Rotation
Type Number of Shares Value of Change Shares Outstanding
Buyers 5/14/11 100,000 $1,263,000 1.00%
Sellers 5/14/11 0 $0 0.00%
Lets hope tomorrow brings good news and a better drug to fight cdif!!
Maybe but that post was un called for.OPTR has potential.
oldberkeley
Your word of caution is warranted and I agree with you. I am hoping for a 20% gain and where most of us got in we haven't even made 10% at this time. It's nice to see a big run up into approval but lately that has not happened. I have read your posts before and you always present realistic views and they are appreciated.
I have a question! The Approval response is due on the 30th which is Memorial Day. I have a hard time believing the FDA is working on that day. Which leads me to believe they'll know the answer either Friday or Saturday.
Having a wife in the med field I know what cdif is and how much of a problem it is.Yes I went over board with my last post but you must admit it is a big deal a real big deal actually.
Can you then please explain how you arrived at $15ish target ? Is that because you got closer to $12+ and a 3 point jump isn't too bad ?
I know the history of VPHM that traded in low 20's purely because of their monopoly on branded Vancomycin which by the way was their only drug that they brought the license for. Vanco was the last standard treatment but still not effective from stopping the relapse that Fido will do as much as 54%. Hospitals will realize this soon...
You two need to do some deep, extensive, difficult, and comprehensive reading about C. difficile, the current treatments, and fidaxomicin. Not to mention learning a bit about business.
The problem with that is that educating yourself is hard work that takes time and patience; posting nonsense is much easier.
Fidaxomicin should be approved; after that you're both in a dream world.
Finished with this board, best of luck to you, over and out.
The revenues should be explosive!!Every hospital, nursing home,VA hospital,extended care facility,In the world will want this.The potentil for third world countries is huge too.Governments will want this for emergancies like whats going on in Japan...Im getting too excited here.
I am expecting to be close to $20 as the revenue potential unfolds upon approval
All time high on Jul 29, 2009 of $15.17
I have to believe that a HUGE pharma company would want to buy OPTR for this dificid drug!!
I agree. OPTR could surpass $15 before the PDUFA date. 25 people of new recruits speaks of some big plans brewing within OPTR
I see we closed at $14.86 in 2009
We should be able to surpass that during this run prob higher maybe much higher.
News out..
Just one small outtake from pr
In addition, treatment with fidaxomicin was associated with a 54% lower risk of recurrence (p< 0.001) and a 1.9-fold greater probability of cure without recurrence
OPTR still rolling on average volume.
I see we tested $13.99 in april,should be no problem hitting that again.Would like to see them announce FDA approval along with sales/income projections at the same time.
Starting to make a little run here.
I seriously expect pps to be close to $20 early June after approval is granted. The potential to kill c-diff with far less relapse rates compared to current standard care is big.
I seriiously expect pps to be close to $20 early June after approval is granted. The potential to kill c-diff with far less relapse rates compared to current standard care is big.
OPTR is my second largest holding as of today.I have BIG hopes for it.
Nice I ride almost daily.Every weekend for sure.But a mountain bike is my ride.
Yes, let's get the word out.
Yes that is me in the picture near the finish of MS150 in Austin.
We need to start posting this on other boards...Is that you in that pic?
This looks to starting to be starting its move up towards the 5/30 approval. Only about 2 weeks left so the late comers to the party will start getting on board.
Hope you dont mind me posting this
From http://www.optimerpharma.com/
In Memoriam:
Christina Donaghy
May 30, 1968 - May 1, 2011
Our beloved colleague and friend, Chrissy Donaghy, Associate Director of Corporate Communications, was in a tragic car accident last weekend and has passed away. A mass will be held in Encinitas on Tuesday, May 10th at 5:00 PM at St John the Evangelist Catholic Church, followed by a "Celebration of Life" at 6:00 PM, at the hall across from the church. In lieu of flowers, Chrissy’s family has requested donations be made in Chrissy’s name to the Surfrider Foundation (www.surfrider.org).
Chrissy's boundless energy, dedication and important contributions as a key corporate communications professional were greatly valued by the company.
Our thoughts and prayers go out to Chrissy’s family, friends and colleagues at this extremely difficult time.
St. John the Evangelist Church is located at
1001 Encinitas Blvd
Encinitas, CA 92024
I was expecting a pr today.The eod was like a battle between red and green,up down up down.
Nice to be in this one today given the rest of the markets.
I agree, considering the market I think that "pretty well" is an understatement.
Best of luck.
Held up pretty well despite a ugly market today. Another 14 trading days to FDA approval date, lets see if it can move up some more by then
Looks like we still have more people reporting results of Dificid this week....
Presentation Information: Title: Immunosuppression and the Risk of Death, Cure Rates and Disease Recurrence Among Patients with Clostridium difficile Infection Presenter: Yoav Golan, M.D., M.S. Date: Tuesday, May 10, 2011 Time: 10:36 a.m. to 10:48 a.m. Central European Time Location: Lecture Hall Brown 1 Oral Session: C. difficile News Presentation #: O504 Poster Presentation Information: Title: Clostridium difficile Recurrence, Alcohol Consumption, and the Effect of Fidaxomicin vs. Vancomycin Presenter: Yoav Golan, M.D., M.S. Date: Tuesday, May 10, 2011 Time: 12:30 p.m. to 1:30 p.m. Central European Time Location: Poster Area Hall 5 Poster Topic 99: Clostridium difficile Poster ID#: P1968 2011 Annual Scientific Meeting of the American Geriatrics Society (AGS), The Gaylord National Hotel, National Harbor, Maryland May 11-14, 2011 Poster Presentation Information: Title: Effect of Advancing Age on Outcomes of Therapy for Clostridium difficile Infection Presenter: Thomas J. Louie, M.D. Date: Thursday, May 12, 2011 Time: 4:30 p.m. to 6:00 p.m. Eastern Time Session: Presidential Poster Session B Location: Exhibit Hall Poster ID#: B126
My only regret is leaving for an hour at the end of trading on Thursday and missing the $12 opportunity!
Still, I'm happy with my $12.26 average and looking forward to the end of the month.
Best of luck.
Get ready for the 13's.
From the PR today, looks like OPTR's drug DIFICID will eat Vancomycin's lunch !!
http://finance.yahoo.com/news/Data-Presented-at-Digestive-prnews-4057287648.html?x=0&.v=1
Just placed my order for more shares tomorrow.Cmon OPTR this could be fun!!!
That's not what the post said that I was responding to. Perhaps it wasn't specific enough.
IV vanco is generic has been for a long time, and is used intravenously for gram positive infections mainly MRSA and enterocci, Viopharma does not make it. Oral vancomyin or Vancocin is Viopharma's main product, the only indication and use is for C-diff and is not effective for anything else, Fidaxomicin will compete against it.
I wouldn't say that it's going to eat into Vanc's market share that much. Vanc is used for many other bacterial infections other that C. diff. Difimicin should do well, nonetheless.
I agree,optimer needs to get their marketing machine in gear as soon as approval is given!!
This stock has $20 written all over it. The findings from the journal adds more to the case that Difimicin will eat into Vanco's market share quickly. Treatment of C-Diff is a huge market and why would anyone prescribe vancomycin when Difimicin is so effective on cutting down the relapse rates as much as 45% ?
Here ya go http://investorshub.advfn.com/boards/board.aspx?board_id=16083
OPTR is the "play of the month"
OH and check out RNN it will be HUGE
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
320
|
Created
|
08/23/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |